Concert Genetic Testing: Gastroenterologic Disorders (non-cancerous)

This policy covers germline and targeted genetic testing and selected non‑invasive serum fibrosis assays for non‑cancerous gastroenterologic disorders — for example HLA‑DQ genotyping to evaluate or rule out celiac disease, HFE C282Y/H63D testing for suspected hereditary hemochromatosis, multigene panels for hereditary pancreatitis, diagnostic/prognostic and monogenic panels for IBD/Crohn’s disease (including VEO‑IBD), and serum tests for liver fibrosis/NASH. Coverage is limited to specific clinical indications and criteria (e.g., HLA testing only to rule out celiac disease and not if previously performed; HFE genotyping only with abnormal iron indices or in affected first‑degree relatives), panels must meet required gene/content specifications, and many algorithmic or off‑criteria panel tests are considered investigational and not covered.

"Genetic testing to confirm diagnosis in patients with signs and/or symptoms of a specific non-cancerous gastroenterologic disorder (e."